This signature, the Grog T regulatory CD4 signature (Grog.Treg.1), did not correlate with higher performance within any of the cancer types it was derived from (Fig. 4A and 4B, Supplemental Table 6).29 It follows that the immune landscape amongst differing cancer types is likely more complex than anticipated. Here, CXCL3 is linked to cancer.